A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
#4PRI RANKED
Most Cited Paper
in Liver Disease Diagnosis and Treatment
18 Months Post-Publication
Class of 2026
“A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
survodutide · dual agonist · glucagon receptor · GLP-1 receptor · Steatohepatitis · Steatohepatitis · Liver fibrosis · fibrosis stage F1-F3 · histologic improvement · Hepatic steatosis reduction · Liver fibrosis improvement · dose-response relationship · Biopsy-confirmed steatohepatitis · Subcutaneous administration · rapid-dose-escalation phase · nausea · diarrhea · vomiting
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Liver Disease Diagnosis and Treatment Papers, Class of 2026. https://pri.pepkio.com/top-papers/liver-disease-diagnosis-and-treatment/2026. Accessed 2026-07-24. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459